News
The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with a fluoropyrimidine chemotherapy (5-FU or capecitabine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback